207 related articles for article (PubMed ID: 32450922)
1. Detecting Subtle Cognitive Impairment in Multiple Sclerosis with the Montreal Cognitive Assessment.
Charest K; Tremblay A; Langlois R; Roger É; Duquette P; Rouleau I
Can J Neurol Sci; 2020 Sep; 47(5):620-626. PubMed ID: 32450922
[TBL] [Abstract][Full Text] [Related]
2. Montreal cognitive assessment for evaluating cognitive impairment in multiple sclerosis: a systematic review.
Rosca EC; Simu M
Acta Neurol Belg; 2020 Dec; 120(6):1307-1321. PubMed ID: 32996098
[TBL] [Abstract][Full Text] [Related]
3. The Cambridge Neuropsychological Test Automated Battery (CANTAB) Versus the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) for the Assessment of Cognitive Function in Patients with Multiple Sclerosis.
Talebi M; Majdi A; Kamari F; Sadigh-Eteghad S
Mult Scler Relat Disord; 2020 Aug; 43():102172. PubMed ID: 32442887
[TBL] [Abstract][Full Text] [Related]
4. The Montreal Cognitive Assessment (MoCA) as a screening test for cognitive dysfunction in multiple sclerosis.
Freitas S; Batista S; Afonso AC; Simões MR; de Sousa L; Cunha L; Santana I
Appl Neuropsychol Adult; 2018; 25(1):57-70. PubMed ID: 27791389
[TBL] [Abstract][Full Text] [Related]
5. Montreal Cognitive Assessment in a Greek sample of patients with multiple sclerosis: A validation study.
Konstantopoulos K; Vogazianos P
Appl Neuropsychol Adult; 2021; 28(1):48-52. PubMed ID: 30939943
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Spanish-language version of the Montreal Cognitive Assessment as a screening test for cognitive impairment in multiple sclerosis.
Gomez-Moreno SM; Cuadrado ML; Cruz-Orduña I; Martínez-Acebes EM; Gordo-Mañas R; Fernández-Pérez C; García-Ramos R
Neurologia (Engl Ed); 2022; 37(9):726-734. PubMed ID: 34836843
[TBL] [Abstract][Full Text] [Related]
7. Validity and sensitivity of Canadian normative data for the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) battery.
Berard JA; Walker LAS
Mult Scler Relat Disord; 2022 Jul; 63():103865. PubMed ID: 35580469
[TBL] [Abstract][Full Text] [Related]
8. Value of the MoCA test as a screening instrument in multiple sclerosis.
Dagenais E; Rouleau I; Demers M; Jobin C; Roger E; Chamelian L; Duquette P
Can J Neurol Sci; 2013 May; 40(3):410-5. PubMed ID: 23603179
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Quick Mild Cognitive Impairment (Qmci) screen to the Montreal Cognitive Assessment (MoCA) in an Australian geriatrics clinic.
Clarnette R; O'Caoimh R; Antony DN; Svendrovski A; Molloy DW
Int J Geriatr Psychiatry; 2017 Jun; 32(6):643-649. PubMed ID: 27427212
[TBL] [Abstract][Full Text] [Related]
10. Screening for cognitive impairment in older adults with hematological malignancies using the Montreal Cognitive Assessment and neuropsychological testing.
Koll TT; Sheese AN; Semin J; Ernst W; High R; Wildes TM; Fisher A; Murman DL
J Geriatr Oncol; 2020 Mar; 11(2):297-303. PubMed ID: 31831362
[TBL] [Abstract][Full Text] [Related]
11. The use of the Montreal Cognitive Assessment (MoCA) screening tool to evaluate cognitive deficits in Lebanese in-patients with schizophrenia.
Haddad C; Salameh P; Sacre H; Clément JP; Calvet B
Asian J Psychiatr; 2022 Apr; 70():103029. PubMed ID: 35189473
[TBL] [Abstract][Full Text] [Related]
12. Screening for Mild Cognitive Impairment: Comparison of "MCI Specific" Screening Instruments.
O'Caoimh R; Timmons S; Molloy DW
J Alzheimers Dis; 2016; 51(2):619-29. PubMed ID: 26890758
[TBL] [Abstract][Full Text] [Related]
13. Digital Screening for Cognitive Impairment - A Proof of Concept Study.
Bloniecki V; Hagman G; Ryden M; Kivipelto M
J Prev Alzheimers Dis; 2021; 8(2):127-134. PubMed ID: 33569558
[TBL] [Abstract][Full Text] [Related]
14. Screening for cognitive impairment with the Montreal Cognitive Assessment in Chinese patients with acute mild stroke and transient ischaemic attack: a validation study.
Zuo L; Dong Y; Zhu R; Jin Z; Li Z; Wang Y; Zhao X; Sachdev P; Zhang W; Wang Y
BMJ Open; 2016 Jul; 6(7):e011310. PubMed ID: 27406642
[TBL] [Abstract][Full Text] [Related]
15. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire.
Benedict RH; Munschauer F; Linn R; Miller C; Murphy E; Foley F; Jacobs L
Mult Scler; 2003 Feb; 9(1):95-101. PubMed ID: 12617275
[TBL] [Abstract][Full Text] [Related]
16. Validity of the Italian multiple sclerosis neuropsychological screening questionnaire.
Migliore S; Landi D; Proietti F; D'Aurizio G; Squitieri F; Mataluni G; Nicoletti CG; Curcio G; Marfia GA
Neurol Sci; 2021 Nov; 42(11):4583-4589. PubMed ID: 33651198
[TBL] [Abstract][Full Text] [Related]
17. Relationship of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) to functional, emotional, and neuropsychological outcomes.
O'Brien A; Gaudino-Goering E; Shawaryn M; Komaroff E; Moore NB; DeLuca J
Arch Clin Neuropsychol; 2007 Nov; 22(8):933-48. PubMed ID: 17851031
[TBL] [Abstract][Full Text] [Related]
18. The Italian validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the application of the Cognitive Impairment Index scoring procedure in MS patients.
Argento O; Incerti CC; Quartuccio ME; Magistrale G; Francia A; Caltagirone C; Pisani V; Nocentini U
Neurol Sci; 2018 Jul; 39(7):1237-1244. PubMed ID: 29704074
[TBL] [Abstract][Full Text] [Related]
19. Screening for brain fog: Is the montreal cognitive assessment an effective screening tool for neurocognitive complaints post-COVID-19?
Lynch S; Ferrando SJ; Dornbush R; Shahar S; Smiley A; Klepacz L
Gen Hosp Psychiatry; 2022; 78():80-86. PubMed ID: 35930974
[TBL] [Abstract][Full Text] [Related]
20. The test accuracy of the Montreal Cognitive Assessment (MoCA) by stroke lateralisation.
Chan E; Altendorff S; Healy C; Werring DJ; Cipolotti L
J Neurol Sci; 2017 Feb; 373():100-104. PubMed ID: 28131163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
